Royalty Pharma Mergers and Acquisitions Summary

Business Services Company

Royalty Pharma has acquired 3 companies, including 3 in the last 5 years.

Royalty Pharma’s largest acquisition to date was in 2017, when it acquired TYSABRI for $2.9B. Royalty Pharma has acquired in 2 different US states. The Company’s most targeted sectors include life science (100%).

Join Mergr and gain access to Royalty Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the business services sector.

M&A Summary

  • M&A Total Activity3
    • M&A Buy Activity3
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 3
  • M&A Advisors 3

Royalty Pharma Plc

110 East 59th Street,
New York, New York 10022
United States,
(212) 883-0200
www.royaltypharma.com

Royalty Pharma is a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates. Royalty Pharma was formed in 1996 and is based in New York, New York.


M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (0.6/yr) # - 1 - 1 - 1 3
vol $2.9B $260M $240M $3.4B
Sell (0.0/yr) # - - - - - - 0
  3

Most Recent M&A

Company Date Value Type
Dicerna - OXLUMO™ (lumasiran) 2021-04-08 240M USD Divestiture
Lexington, Massachusetts
Arteaus Therapeutics LLC - Emgality Royalty 2019-04-01 260M USD Divestiture
Cambridge, Massachusetts
TYSABRI (natalizumab) 2017-02-27 2.9B USD Divestiture
, United States · www.tysabri.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 3 (100%) 3.4B (100%) - -
Total 3 $3.4B - -

By Geo

State/Country Buy Value Sell Value
United States 3 3.4B - -
  Massachusetts 2 500M - -
Total 3 $3.4B - -

Top M&A Advisors

Legal Deals
Jones Day
2
Maiwald Patentanwalts- und Rechtsanwalts-GmbH
2
Gibson, Dunn & Crutcher LLP
1

Deal Values

buy # Total
> $1B 1 $2.9B
$100M to $1B 2 $500M
TOTAL $3.4B
Largest TYSABRI (natalizumab)
$2.9B (2017-02-27)

M&A Connections

Deals
Acquired from
Strategic(s)
100%
3 (100%)

 Subscribe to unlock this and 164,130
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.1K Private Equity Firms
  • 153K M&A Transactions
  • 160K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 49K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.